Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,153,584
  • Shares Outstanding, K 94,892
  • Annual Sales, $ 1,040 K
  • Annual Income, $ -298,410 K
  • EBIT $ -478 M
  • EBITDA $ -490 M
  • 60-Month Beta 0.20
  • Price/Sales 3,296.94
  • Price/Cash Flow N/A
  • Price/Book 4.90

Options Overview Details

View History
  • Implied Volatility 51.04% (-7.45%)
  • Historical Volatility 57.39%
  • IV Percentile 4%
  • IV Rank 19.98%
  • IV High 95.22% on 12/17/25
  • IV Low 40.01% on 08/15/25
  • Expected Move (DTE 2) 3.41 (6.29%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 368
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 12,840
  • Open Int (30-Day) 12,366
  • Expected Range 50.81 to 57.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.36
  • Number of Estimates 8
  • High Estimate -1.20
  • Low Estimate -1.52
  • Prior Year -0.88
  • Growth Rate Est. (year over year) -54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.04 +26.01%
on 12/18/25
57.99 -6.48%
on 01/05/26
+3.74 (+7.42%)
since 12/12/25
3-Month
38.81 +39.73%
on 11/07/25
57.99 -6.48%
on 01/05/26
+10.19 (+23.12%)
since 10/14/25
52-Week
24.10 +125.04%
on 04/09/25
57.99 -6.48%
on 01/05/26
+18.62 (+52.26%)
since 01/14/25

Most Recent Stories

More News
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified...

CRNX : 54.82 (+0.94%)
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of...

CRNX : 54.82 (+0.94%)
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of...

CRNX : 54.82 (+0.94%)
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant...

CRNX : 54.82 (+0.94%)
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30...

CRNX : 54.82 (+0.94%)
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will...

CRNX : 54.82 (+0.94%)
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational...

CRNX : 54.82 (+0.94%)
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted...

CRNX : 54.82 (+0.94%)
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients...

CRNX : 54.82 (+0.94%)
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community...

CRNX : 54.82 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 57.72
2nd Resistance Point 56.98
1st Resistance Point 55.64
Last Price 54.82
1st Support Level 53.56
2nd Support Level 52.82
3rd Support Level 51.48

See More

52-Week High 57.99
Last Price 54.82
Fibonacci 61.8% 45.04
Fibonacci 50% 41.05
Fibonacci 38.2% 37.05
52-Week Low 24.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar